Top news of the week: 27.10.2021.
Companies And Industries
BMS Buyout Rumors Send Canadian Biopharma’s Stock Soaring
Bristol Myers Squibb is reportedly courting Canada's Aurinia Pharmaceuticals to strike a buyout deal.
Two Biopharmas Nix IPO Plans in Unstable Market
Numerous biopharma and life sciences companies have sought to put their stocks up for sale, but this week, two companies opted to pull out their IPO due to concerns over market stability.
BioSpace Movers & Shakers, Oct. 22
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Clinical Catch-Up: October 18-22
It was yet another busy week for clinical trial news. Here’s a look.
AstraZeneca Cancer Trial Hit with Clinical Hold Following Cardiac Issues
An experimental AstraZeneca cancer drug trial has been placed on hold due to safety concerns. This news comes two years after Amgen was also forced to pause a study of a drug within the ...
GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody
Oncology biotech Atreca is linking arms with the Bill & Melinda Gates Medical Research Institute to work on a monoclonal antibody for the potential treatment of malaria. The licensing deal ...
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: a slow start for Biogen’s Aduhelm; J&J looks to transition COVID vaccine to commercial sales; 2seventy bio spins out from ...
Vertex Gains In Vivo CRISPR Foothold With Mammoth Pact
<span>Deal Snapshot: The nearly $700m deal gives Vertex, already with a major foothold in CRISPR, access to Mammoth’s ultra-compact gene-editing technology in two diseases.</span>